| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
The prevalence of Japanese cedar pollinosis (JCP) has been increasing, and is currently around 30%. JCP is now called a part of Japanese national disease, but until now there has been no treatment to improve the allergy constitution in a short term regimen. Therefore, we developed a new oral immunotherapy to take antigen-galactomannan conjugate capsules using intestinal immunity. In addition, the treatment period is very short for about 2 months before and after the pollen is scattered. In this RCT, OIT with antigen-galactomannan conjugate was safe and approved to reduce anti-allergic medicine by about 60% compared to standard treatment.In the near future, there is a possibility that it will lead to a new immunotherapy to improve the allergy constitution.
|
